⇨ Takeda’s Cambridge, MA-based oncology group has struck a discovery deal with Austin-based Shattuck Labs. The deal centers on a combo immuno-oncology approach to drug development, matching a checkpoint strategy with whipping up a T cell attack. Takeda will offer Shattuck unspecified research support in exchange for control of two pre-clinical and four discovery stage cancer programs.
⇨ A few weeks after getting a complete response letter from the FDA for its prior approval supplement of oxy alternative Oxaydo, the Wayne, PA-based Egalet $EGLT has begun cutting staff. In a release the company said it would lay off 40% of its non-sales staff. The CRL proved a nasty setback for the biotech’s stock.
⇨ Alexion Pharmaceuticals and Sema4 inked a strategic partnership to “leverage their shared experience in data science and systems biology to accelerate rare disease diagnosis and therapeutic discovery.”
⇨ The gene therapy biotech Orchard Therapeutics has recruited PTC vet Mark Rothera as its new CEO. Rothera had been the chief commercial officer of the Duchenne muscular disease biotech.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.Free Subscription